Analysts

JPMorgan Chase GSK

JPMorgan Analysts Highlight Reopening Biotech IPO Market Amid Continued Big Pharma M&A Activity

The biotech sector is experiencing a resurgence in public market activity, but many leading companies may prefer acquisition by larger pharmaceutical firms over pursuing initial public offerings (IPOs). This trend reflects a selective investment climate and a strategic shift in how biotech firms approach growth and funding.
CrowdStrike Holdings

Analysts Virtus Investment Partners recommend buying CrowdStrike Holdings (CRWD) shares amid strong cybersecurity demand

CrowdStrike Holdings remains a compelling investment opportunity despite its recent price surge, according to Joe Terranova of Virtus Investment Partners, who believes the stock has further growth potential amid rising demand for cybersecurity solutions linked to artificial intelligence.